Fig. 4: PFS and OS duration in HR + /HER2− mBC patients treated with PI3Ki alpelisib and ET. | npj Breast Cancer

Fig. 4: PFS and OS duration in HR + /HER2− mBC patients treated with PI3Ki alpelisib and ET.

From: Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies

Fig. 4

A PFS duration in 2L+. B OS duration in 2L+. IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, PFS progression-free survival, OS overall survival, PI3Ki phosphoinositide 3-kinase inhibitor, ET endocrine therapy, 2L+ second line and beyond, HR+ hormone receptor-positive, HER2− human epidermal growth factor receptor 2-negative.

Back to article page